MESANTOIN
LOE ApproachingNDAORALTABLET
Approved
Oct 1946
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 6d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MESANTOIN (mephenytoin) is an oral small-molecule antiepileptic drug approved in 1946 for seizure management. The exact mechanism of action and current indications are not fully documented in available data, but it is a historic anticonvulsant used in epilepsy therapy. This is a legacy product with a 78-year commercial history.
LOE Approaching
With lifecycle status 'LOE Approaching' and moderate competitive pressure (30/100), the brand team is likely in maintenance or wind-down mode with minimal headcount expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and a product in LOE-approaching stage, this is a legacy portfolio holding with minimal hiring momentum. Career mobility is limited; positions are primarily maintenance-focused rather than growth-oriented.
Brand ManagerMedical Science Liaison
Worked on MESANTOIN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.